Medical experts highlight nutrition survey data during 20th PENSA Congress 2019 in Hong Kong (FOTO)

Bad Homburg (ots) - Fresenius Kabi held its United for Clinical Nutrition (UCN)
Satellite Symposium during the 20th Congress of Parenteral and Enteral Nutrition
Society of Asia (PENSA) on October 9, 2019, in Hong Kong.

The symposium's featured topic was the UCN Nutrition Insights Day Asia (NID), a
comprehensive survey led by an advisory board and supported by Fresenius Kabi
that provides insights into clinical nutrition practices in 83 hospitals in
India, Indonesia, the Philippines, South Korea, Taiwan, Thailand and Vietnam.

Leading clinical nutrition experts were present to discuss UCN NID: Prof.
Alessandro Laviano (Italy), Prof. Rajeev Joshi (India), Prof. Han-Hsui Hsu
(Taiwan), Dr. Jesus Fernando B. Inciong (Philippines), Dr. Winai Ungpinitpong
(Thailand), and Prof. Jeong-Meen Seo (South Korea).

As nutritional deficits continue to burden the global healthcare system, the
panel of experts emphasized the importance of prioritizing patients' nutritional
needs in order to effectively enhance post-admission recovery. Prof. Seo said,
"The time is now. No more excuses. We must work together to bring clinical
nutrition forward."

NID results will soon be available at www.unitedforclinicalnutrition.com.

About 'United for clinical nutrition'

In 2014, Fresenius Kabi established UCN to raise awareness for disease-related
malnutrition around the world. Through regional data collection and clinical
assessment, and tailored events and tools for healthcare professionals, UCN aims
to reduce the prevalence of hospital malnutrition. In 2018, the initiative
expanded in Asia. To learn more, visit www.unitedforclinicalnutrition.com.

About Fresenius Kabi

Fresenius Kabi is a global healthcare company that specializes in lifesaving
medicines and technologies for infusion, transfusion and clinical nutrition. The
company's products and services are used to help care for critically and
chronically ill patients. Fresenius Kabi's product portfolio comprises a
comprehensive range of I.V. generic drugs, infusion therapies and clinical
nutrition products as well as the devices for administering these products. In
the field of biosimilars, we focus on autoimmune diseases and oncology. In 2019,
the first biosimilar product by Fresenius Kabi was launched. Within transfusion
medicine and cell technologies, Fresenius Kabi offers products for collection
and processing of blood and cell components.

With its corporate philosophy of "caring for life", the company is committed to
putting essential medicines and technologies in the hands of people who help
patients and finding the best answers to the challenges they face.

For more information, please visit www.fresenius-kabi.com.

For press inquiries, please contact:
Nina Espiritu
Edelman GmbH
Barmbeker Str 4, 22303 Hamburg, Germany
T: +49 (0)69 401254-345
nina.espiritu@edelman.com

Additional content: https://www.presseportal.de/pm/106045/4460426
OTS: Fresenius Kabi Deutschland GmbH

Original-Content von: Fresenius Kabi Deutschland GmbH, übermittelt durch news aktuell